MXCT
MAXCYTE, INC.
NASDAQ · Healthcare · Medical - Devices · US
$1.19
−0.42%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.22
From 52W high−34.97%
Volume485022.00
Market cap$122.82M
P/E (TTM)—
P/S (TTM)4.0x
Div yield—
Key dataSep 18, 2026
Open
$1.22
From 52W high
−34.97%
Volume
485022.00
Market cap
$122.82M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
P/E (TTM)
—
RSI (14)
42.2
MomentumView details →
1D Return
−0.42%
YTD Return
−24.84%
SummaryUpdated Jun 1, 2026
MaxCyte, Inc. (NASDAQ:MXCT) is a global life sciences company founded in 1998 and headquartered in Rockville, Maryland. The company specializes in cell engineering technology that enables the development of next-generation cell therapies. MaxCyte went public in July 2021 and has established itself as a key enabler in the emerging cell and gene therapy industry. The company's electroporation technology platform has supported the development of CASGEVY, the first FDA-approved non-viral cell therapy, and maintains partnerships with numerous biotechnology and pharmaceutical companies developing cell-based treatments.
Similar companies
Latest newsMore news →
MaxCyte granted inducement stock options for 220,000 shares and a restricted stock unit award for 110,000 shares to Sidharth Kapileshwar in connection with his commencement of employment as Senior Vice-President, Chief Corporate Development Officer.9d agoMaxCyte, Inc. launched the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays, available through its SeQure™ service, to improve off-target assessment for genome editing therapies.32d ago